Interventional Spine received U.S. Food and Drug Administration clearance for its Lateral Opticage Expandable Intervertebral Body Fusion Device.
The lumbar intervertebral body fusion device is indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1. It can be implanted via posterior, transforaminal or lateral approach.
The device is a part of Interventional Spine's family of Opticage Expandable Interbody Fusion Devices cleared for TLIF earlier this year.
More articles on devices:
Investor notes: 6 spine device company updates
Yale student scoliosis brace tracking device startup gets $100k
Vivex Biomedical acquires University of Miami Tissue Bank assets